Information Provided By: 
Fly News Breaks for August 4, 2015
ENDP, VRX, BXLT, SHPG, PFE, AGN
Aug 4, 2015 | 14:45 EDT
JPMorgan analyst Chris Schott said that Shire's (SHPG) unsolicited offer for Baxalta (BXLT) highlights the accelerating pace of M&A in the pharmaceutical sector. Schott, who told investors he sees heightened pressure for companies to stay active in terms of business development, pointed toward Allergan (AGN) and Pfizer (PFE) as having the most near-term capacity for deals. The analyst noted he has Overweight ratings on each of those two stocks, as well as on other potential acquirers Valeant (VRX) and Endo (ENDP).
News For AGN;PFE;SHPG;BXLT;VRX;ENDP From the Last 2 Days
PFE
Apr 22, 2024 | 08:13 EDT
Pfizer announced that the European Commission, or EC, has granted marketing authorization for Emblaveo for the treatment of adult patients with complicated intra-abdominal infections, or cIAI, hospital-acquired pneumonia, or HAP, including ventilator-associated pneumonia, or VAP, and complicated urinary tract infections, or cUTI, including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
